TruSight Oncology 500是一种新一代测序（NGS）肿瘤分析方法，可分析数百种与癌症有关的生物标记。它能够鉴定各种肿瘤类型中涉及的所有相关DNA和RNA变异。
此外，它还能准确测量关键免疫疗法生物标记：肿瘤突变负荷（TMB）和微卫星不稳定性（MSI）。
通过测试整合可节省时间、费用和样本
获得可信度高的结果
解锁免疫肿瘤学
Input Recommendations for TMB, MSI, and Small Variant Analysis with TruSight Oncology 500
Technical Note | HTML
Analysis of TMB and MSI Status with TruSight Oncology 500
Application Note | HTML
Analysis of TruSight Oncology 500 data with PierianDx Clinical Genomics Workspace Software
Brochure | PDF< 1 MB
TruSight Oncology 500 Demo Program Flyer
Brochure | PDF< 1 MB
TruSight Oncology 500 datasheet
Data Sheet | HTML
Comprehensive next-generation sequencing (NGS) assay that targets DNA and RNA variants from the same FFPE sample.
TruSight Oncology is a set of NGS platform reagents for the detection of cancer variants, using an enrichment-based method to simultaneously analyze DNA and RNA. Gene content is not included.
Provides comprehensive gene fusion detection in formalin-fixed, paraffin-embedded (FFPE) and other cancer research samples.
